Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products

BACKGROUND: The use of pharmacokinetic (PK) studies to help design personalized prophylaxis regimens for factor VIII (FVIII) concentrate in individuals with hemophilia A has been recognized for many years but only became practical for routine clinical use with the availability of web‐accessible population PK applications based on Bayesian analysis. OBJECTIVE: To compare PK variables using population PK studies done on 2 extended half‐life recombinant FVIII concentrates in 23 individuals with hemophilia A after switching from one product to the other. METHODS: We retrospectively analyzed PK parameters derived from the Web‐Accessible Population Pharmacokinetic Service‐Hemophilia (WAPPS‐HEMO) application on 23 individuals with severe or moderately severe hemophilia A who were required to switch from recombinant FVIII Fc (Eloctate; Biogen, Cambridge, MA, USA) to recombinant antihemophilic factor PEGylated (Adynovate; Takeda Pharmaceutical Company, Osaka, Japan) between 2016 and 2017. RESULTS: There were minor PK differences between Eloctate and Adynovate, but some parameters did reach statistical significance, namely in vivo recovery (mean, 2.73 IU/dL per IU/kg vs 2.41 IU/dL per IU/kg), clearance (mean, 0.163 mL/h vs 0.194 mL/h), and volume of distribution at steady state (mean, 42.5 ml/kg vs 49.8 mL/kg). Smaller nonsignificant trends toward higher values for Adynovate were seen in terminal half‐life, area under the curve, and predicted times to 5% and 1% residual FVIII after infusion. CONCLUSION: Population PK analysis revealed differences between the two extended half‐life FVIII concentrates, reaching significance for in vivo recovery, clearance, and volume of distribution.